198226-62-9

Basic information

• Product Name: Benzonitrile,2-chloro-6-(2-oxiranylmethoxy)-
• Synonyms: Benzonitrile,2-chloro-6-(oxiranylmethoxy)- (9CI)
• CAS NO: 198226-62-9
• Molecular Formula: C10H8 Cl N O2
• Molecular Weight: 209.632
• Mol File: 198226-62-9.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Benzonitrile,2-chloro-6-(2-oxiranylmethoxy)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzonitrile,2-chloro-6-(2-oxiranylmethoxy)-(198226-62-9)
• EPA Substance Registry System: Benzonitrile,2-chloro-6-(2-oxiranylmethoxy)-(198226-62-9)

Safety Data

• Hazardous Substances Data: 198226-62-9(Hazardous Substances Data)

Upstream product

• 89999-90-6 3-chloro-2-cyanophenol 
• 106-89-8 epichlorohydrin 
• 152333-94-3 glycidyl nosylate 
• 1056958-45-2 C₉H₆ClNO₂ 
• 668-45-1 2-chloro-6-fluorobenzonitrile 

Downstream Products

• 246155-21-5 (R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]-1,1-dimethyl-4-(2-carbethoxyphenyl)butylamine Hydrochloride 
• 246155-23-7 (R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]-1,1-dimethyl-4-(3-carbethoxyphenyl)butylamine Hydrochloride 
• 246155-24-8 (R)-N-[2-Hydroxy-3-(3-chloro-2-cyanophenoxy)propyl]-1,1-dimethyl-4-(4-carbethoxyphenyl)butylamine Hydrochloride 
• 1187330-93-3 2-chloro-6-(2-hydroxy-3-((2-methyl-1-(naphthalen-2-yl)propan-2-yl)amino)propoxy)benzonitrile 
• 198226-53-8 2-chloro-6-([(2R)-2-oxiranylmethyl]oxy)benzonitrile 
• 284035-33-2 NPS 2143 
• 867040-05-9 Acetic acid (S)-2-(3-chloro-2-cyano-phenoxy)-1-chloromethyl-ethyl ester 
• 867040-04-8 (+/-)-2-chloro-6-(3-chloro-2-hydroxypropoxy)benzonitrile 

Relevant articles and documents

Synthesis of the calcilytic ligand NPS 2143

(R)-3 (NPS 2143) is a negative allosteric modulator of the human calcium-sensing receptor (CaSR) and as such represents an important pharmacological tool compound for studying the CaSR. Herein, we disclose for the first time a complete experimental description, detailed characterisation and assessment of enantiomeric purity for (R)-3. An efficient, reproducible and scalable synthesis of (R)-3 that requires a minimum of chromatographic purification steps is presented. (R)-3 was obtained in excellent optical purity (er > 99:1) as demonstrated by chiral HPLC and the pharmacological profile for (R)-3 is in full accordance with that reported in the literature.

Method of using calcilytic compounds

The present invention features calcilytic compounds. "Calcilytic compounds" refer to compounds able to inhibit calcium receptor activity. Also described are the use of calcilytic compounds to inhibit calcium receptor activity and/or achieve a beneficial effect in a patient; and techniques which can be used to obtain additional calcilytic compounds.